Protagonist Therapeutics Inc (PTGX)

04:09 AM

What dividend safety score for Protagonist Therapeutics Inc. stock2025 Earnings Surprises & Trade Opportunity Analysis Reports - Newser

04:09 AM

Dec 04, 2025

How currency fluctuations impact Protagonist Therapeutics Inc. stock2025 Year in Review & Scalable Portfolio Growth Ideas - Newser

Dec 04, 2025

Dec 03, 2025

How Protagonist Therapeutics Inc. stock compares to growth peers2025 Earnings Surprises & High Accuracy Investment Entry Signals - Newser

Dec 03, 2025

Dec 03, 2025

Prudential Financial Inc. Has $4.28 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Dec 03, 2025

Dec 03, 2025

Legal & General Group Plc Grows Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Dec 03, 2025

Dec 03, 2025

Capital Fund Management S.A. Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Dec 03, 2025

Dec 03, 2025

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Foster's Daily Democrat

Dec 03, 2025

Dec 03, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Nasdaq Futures Therapeutic Edge - Kalkine Media

Dec 03, 2025

Dec 02, 2025

Skandinaviska Enskilda Banken AB publ Lowers Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Dec 02, 2025

Nov 30, 2025

Trading Systems Reacting to (PTGX) Volatility - news.stocktradersdaily.com

Nov 30, 2025

Nov 30, 2025

Ensign Peak Advisors Inc Decreases Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Nov 30, 2025

Nov 30, 2025

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - Daytona Beach News-Journal

Nov 30, 2025

Nov 30, 2025

Protagonist Therapeutics, Inc. $PTGX Shares Purchased by American Century Companies Inc. - MarketBeat

Nov 30, 2025

Nov 30, 2025

Protagonist Therapeutics (PTGX) Price Target Increased by 16.48% to 91.65 - MSN

Nov 30, 2025

Nov 28, 2025

Protagonist Therapeutics, Inc. $PTGX Shares Bought by Creative Planning - MarketBeat

Nov 28, 2025

Nov 28, 2025

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Oak Ridger

Nov 28, 2025

Nov 27, 2025

Why Protagonist Therapeutics Inc. stock remains undervaluedDividend Hike & Fast Moving Stock Trade Plans - BỘ NỘI VỤ

Nov 27, 2025

Nov 27, 2025

Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance

Nov 27, 2025

Nov 27, 2025

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice - Newswire :) Press Release Distribution

Nov 27, 2025

Nov 26, 2025

Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat

Nov 26, 2025

Nov 26, 2025

Protagonist Therapeutics Reaches Analyst Target Price - Nasdaq

Nov 26, 2025

Nov 25, 2025

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Daily Commercial

Nov 25, 2025

Nov 25, 2025

Jefferies Financial Group Inc. Buys 192,126 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Nov 25, 2025

Nov 25, 2025

120,159 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Segall Bryant & Hamill LLC - MarketBeat

Nov 25, 2025

Nov 24, 2025

[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity - Stock Titan

Nov 24, 2025

Nov 24, 2025

Geode Capital Management LLC Buys 20,671 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Nov 24, 2025

Nov 23, 2025

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Courier & Press

Nov 23, 2025

Nov 23, 2025

Intech Investment Management LLC Acquires 2,971 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Nov 23, 2025

Nov 21, 2025

Envestnet Asset Management Inc. Grows Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Nov 21, 2025

Nov 20, 2025

Protagonist Therapeutics stock maintains Buy rating at Jefferies on pipeline potential - Investing.com Canada

Nov 20, 2025

Nov 20, 2025

What hedge fund activity signals for Protagonist Therapeutics Inc. stockWall Street Watch & Real-Time Chart Breakout Alerts - newser.com

Nov 20, 2025

Nov 19, 2025

How rising interest rates impact Protagonist Therapeutics Inc. stockRate Hike & Entry Point Strategy Guides - newser.com

Nov 19, 2025

Nov 19, 2025

How Protagonist Therapeutics Inc. stock responds to policy changesTrade Risk Summary & Weekly Top Gainers Trade List - newser.com

Nov 19, 2025

Nov 19, 2025

Officer Molina Surrenders 2,712 Of Protagonist Therapeutics Inc [PTGX] - TradingView

Nov 19, 2025

Nov 19, 2025

Is Protagonist Therapeutics Inc. stock entering bullish territoryCPI Data & Advanced Technical Analysis Signals - newser.com

Nov 19, 2025

Nov 19, 2025

What risks investors should watch in Protagonist Therapeutics Inc. stockEarnings Recap Report & Daily Oversold Stock Bounce Ideas - newser.com

Nov 19, 2025

Nov 19, 2025

Is Protagonist Therapeutics Inc. stock cheap compared to fundamentalsMarket Growth Summary & Weekly Top Gainers Trade List - newser.com

Nov 19, 2025

Nov 18, 2025

Protagonist Therapeutics expands scope of peptide therapeutics - Traders Union

Nov 18, 2025

Nov 18, 2025

Protagonist Therapeutics, Inc. $PTGX is Knott David M Jr's 9th Largest Position - MarketBeat

Nov 18, 2025

Nov 18, 2025

Protagonist Therapeutics Opens with 27.21% Gain Amidst Market Decline - Markets Mojo

Nov 18, 2025

Nov 17, 2025

Persistent Asset Partners Ltd Takes Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Nov 17, 2025

Nov 17, 2025

Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Bank of New York Mellon Corp - MarketBeat

Nov 17, 2025